Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
- 1.5k Downloads
NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumors) is the first study to compare biological and clinical activity of fulvestrant 500 versus 250 mg in the neoadjuvant breast cancer setting. We hypothesized that fulvestrant 500 mg may be superior to 250 mg in blocking estrogen receptor (ER) signaling and growth. A multicenter, randomized, open-label, Phase II study was performed to compare fulvestrant 500 mg (500 mg/month plus 500 mg on day 14 of month 1) versus fulvestrant 250 mg/month for 16 weeks prior to surgery in postmenopausal women with ER+ locally advanced breast cancer. Core biopsies at baseline, week 4, and surgery were assessed for biomarker changes. Primary endpoint: change in Ki67 labeling index (LI) from baseline to week 4 determined by automated computer imaging system (ACIS). Secondary endpoints: ER protein expression and function; progesterone receptor (PgR) expression; tumor response; tolerability. ER and PgR were examined retrospectively using the H score method. A total of 211 patients were randomized (fulvestrant 500 mg: n = 109; 250 mg: n = 102). At week 4, fulvestrant 500 mg resulted in greater reduction of Ki67 LI and ER expression versus 250 mg (−78.8 vs. −47.4% [p < 0.0001] and −25.0 vs. −13.5% [p = 0.0002], respectively [ACIS]); PgR suppression was not significantly different (−22.7 vs. −17.6; p = 0.5677). However, H score detected even greater suppression of ER (−50.3 vs. −13.7%; p < 0.0001) and greater PgR suppression (−80.5 vs. −46.3%; p = 0.0018) for fulvestrant 500 versus 250 mg. At week 16, tumor response rates were 22.9 and 20.6% for fulvestrant 500 and 250 mg, respectively, with considerable decline in all markers by both ACIS and H score. No detrimental effects on endometrial thickness or bone markers and no new safety concerns were identified. This provides the first evidence of greater biological activity for fulvestrant 500 versus 250 mg in depleting ER expression, function, and growth.
KeywordsEstrogen receptor-positive breast cancer Fulvestrant 500 mg Faslodex® Neoadjuvant Biomarkers
The authors gratefully acknowledge the collaboration of the Munich Study Centre, Munich, Germany, and would like to thank Sandra Cuscó, PhD, from Complete Medical Communications, who provided medical writing support funded by AstraZeneca. Final approval of the manuscript lay solely with the authors. The NEWEST study was funded by AstraZeneca.
Conflict of interests
Irene Kuter, Jose Bines and Nadia Harbeck have acted as consultants to or in advisory roles to AstraZeneca. Julia Gee and Robert Nicholson have received research funding from AstraZeneca. Elizabeth Lowe and Ugochi Emeribe are employees of AstraZeneca and hold stock ownership with AstraZeneca. Elizabeth Anderson and Francisco Sapunar are former employees of AstraZeneca. Elizabeth Anderson holds stock ownership with AstraZeneca. Roberto Hegg, Christian Singer and Rajendra Badwe have no conflicts of interest to disclose.
- 3.Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JFR, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664–1670PubMedCrossRefGoogle Scholar
- 4.DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baum H, Walton P, Sutcliffe FA, Wakeling AE (1994) Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54:408–414PubMedGoogle Scholar
- 5.Di Leo A, Jerusalem G, Petruzelka L, Bondarenko I, Khasanov R, Verhoeven D, Pedrini J, Smirnova I, Lichinitser M, Pendergrass K, Garnett S, Lindemann JPO, Sapunar F, Martin M, on behalf of the CONFIRM investigators (2010) Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28:4594–4600PubMedCrossRefGoogle Scholar
- 6.Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, Letrozole Neo-Adjuvant Breast Cancer Study Group (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527–1532PubMedCrossRefGoogle Scholar
- 8.Jasani B, Douglas-Jones A, Rhodes A, Wozniak S, Barrett-Lee PJ, Gee J, Nicholson R (2006) Measurement of estrogen receptor status. In: Brooks SA, Harris A (eds) Methods in molecular medicine: breast cancer research protocols, 1st edn. Humana Press, New YorkGoogle Scholar
- 9.Messersmith W, Oppenheimer D, Peralba J, Sebastiani V, Amador M, Jimeno A, Embuscado E, Hidalgo M, Iacobuzio-Donahue C (2005) Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biol Ther 4:1381–1386PubMedCrossRefGoogle Scholar
- 12.Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M (2001) Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5 (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61:6739–6746PubMedGoogle Scholar
- 13.Robertson JFR, Lindemann J, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Emerson L, Dean A, Ellis MJ (2010) A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the ‘FIRST’ study. Cancer Res 70: abstract S1–S3Google Scholar
- 15.Robertson JFR, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:229–238PubMedCrossRefGoogle Scholar
- 16.Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists’ Group (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116PubMedCrossRefGoogle Scholar
- 17.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
- 18.Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Wians FH Jr, Hynan L, Ashfaq R (2001) Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 116:495–503PubMedCrossRefGoogle Scholar